Skip to main content
. Author manuscript; available in PMC: 2024 Feb 13.
Published in final edited form as: Cancer Cell. 2023 Feb 13;41(2):340–355.e6. doi: 10.1016/j.ccell.2023.01.007

Figure 7. CD70 targeting has potent anti-tumor cell activity in vivo.

Figure 7.

(A) Growth rate of HCC827-CD70 xenografts treated with CD70-targeting cusatuzumab (Cus)-MMAE, control IgG antibodies, or an irrelevant ADC - brentuzimab (Bren)-MMAE) (n = 9 mice/group). *p < 0.0001 vs control. (B) Effect of wild-type (WT) NK cells or CD70-targeting CAR NK cells on HCC827-CD70 xenografts (n = 9 mice/group). *p < 0.0001. (C) Growth rate of H1975 OR17 xenografts treated with IgG antibodies, osimertinib (OSI), Cus-MMAE, or the combination (n = 7–8 mice/group). *p < 0.0001 vs control. (D) Growth H1975 OR17 xenografts treated with wild-type NK cells or CD70-targeting CAR NK cells (n = 7–8mice/group). *p < 0.0001 vs control; p<0.0001 vs control NK cells. For all graphs, data are mean ± SEM.